Paradigm Biopharmaceuticals (ASX:PAR) drew down the remaining balance of tranche 4, valued at $2 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Friday Australian bourse filing.
Following the drawdown, about $5 million remains available under the facility, providing continued financial flexibility to support phase 3 execution and broader commercial readiness activities, the filing added.
The company's shares plunged 13% in recent Friday trade.